The Middle-East and Africa Bovine Respiratory Disease Treatment Market has been estimated at USD 3.28 million in 2018 and is projected to reach USD 8.9 million by 2023, at a CAGR of 22.1% during the forecast period from 2018 to 2023.
Bovine respiratory disease (BRD) has a multifactorial, polymicrobial etiology. Organisms known to be related with BRD include bacteria and viruses. BRD is a shared health problem for both dairy and beef cattle, ensuing in economic loses. There are many factors that combine to cause disease. No two scenarios are precisely same but they often culminate in severe and fatal bacterial pneumonia.
Bovine respiratory disease complex (BRDC) is a substantial reason of mortality and morbidity in cattle; resulting into loss of million dollars annually for the dairy and beef industries, even with the use of vaccines and antibiotics.
The Middle-East and Africa bovine respiratory disease treatment market has been segmented on the basis of type of treatment into anti-infectious agents, anti-parasiticides, bronchodilators, oral rehydration fluids, non-steroidal anti-inflammatories, and mucolytic. Anti-infectious can be further sub-segmented into antibiotics and sulfas. Antibiotics and anti-inflammatory drugs are now being used for combination treatment and expected to improve the success rate of the treatment. Middle-East and Africa market is geographically segmented into Middle-East and Africa.
The major companies dominating this market by their products and services are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A, Ceva Sante Animale and Vétoquinol S.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Infectious Agents
5.1.1.1 Antibiotics
5.1.1.2 Sulfas
5.1.2 Anti-Parasiticides
5.1.3 Bronchodilators
5.1.4 Oral Rehydration Fluids
5.1.5 Non-Steroidal Anti-Inflammatories
5.1.6 Mucolytics
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zoetis Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck & Co. Inc.
8.3 Bayer Corporation
8.4 Eli Lilly & Co.
8.5 Merial S.A.S
8.6 Boehringer Ingelheim Vetmedica
8.7 Novartis Animal Health
8.8 Vibrac S.A
8.9 Ceva Sante Animale
8.10 Vétoquinol S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
